Any current/future new fundraising through debt or equity?

Currently, Thyrocare has about ₹30 crores of debt with a three-year tenure against assets, with no bank guarantee or collateral. In the immediate next 3 to 6 months, there is no plan for further debt funding as the company has enough cash. Future CAPEX investments will be evaluated to decide between equity, cash, or debt, depending on the best available options. The management views taking debt for healthcare equipment financing as prudent and cost-effective compared to using equity. They are open to taking more term loans if needed for business CAPEX, but no firm decision has been mad

Any current/future capex/capital investment/strategic investment?

H1 FY24 CAPEX spent: Rs. 46 crores. - Rs. 16-17 crores on replacing 24 old machines. - Rs. 16 crores on lab infrastructure improvements and expansions. - Rs. 6 crores on LLP investments. - Remaining on IT and other CAPEX. H2 FY24 planned CAPEX: - Rs. 5 crores to replace older machines. - Rs. 5 crores on physical infrastructure and IT overhaul. - Rs. 10 crores on international expansion, primarily Tanzania lab setup. - Total anticipated Rs. 20 crores in H2 FY24. FY25 estimated CAPEX: Around Rs. 50 crores (mainly maintenance CAPEX and expansions). Capital advances of Rs. 16 cr

Future growth expectations in sales/revenue/volumes?

Franchise business revenue grew about 20% YoY with 8% volume growth; remaining growth driven by price mix (Rahul Guha, Page 17). Price hikes were marginal at 4-5%, major growth achieved through mix of larger Aarogyam packages, Jaanch test menu, vitamins, etc. Jaanch brand (diagnostic packages) reached ₹1 crore per month within 3 months and targets ₹25-30 crores revenue next year (Page 13). Hospital channel expansion is slow with only 2-3 hospitals currently, business still learning and not material yet (Page 14). Nuclear business expected to reach profitability with ₹12-12.5 crores qua

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates stable EBITDA margins in the 28-30% range for FY '24, with limited operating leverage due to ongoing investments in growth and business promotion. Operating leverage is expected to start kicking in from FY '25 onwards, potentially improving profitability. Nuclear business EBITDA margins are constrained by old equipment maintenance costs; normalized EBITDA expected around current levels, with growth in revenue to 12-12.5 crores quarterly expected by H1 FY '25. Franchise business grew 20% YoY, partnership business (excluding API & B2G) grew 22%, indicating strong revenue

Current/ Expected Orderbook/ Pending Orders?

The company has recently won government contracts for TB testing in Gujarat and Assam. These contracts total approximately ₹4.5 crores annually with a tenure of one year. Work on these contracts started from the current month of the call. The government business is still in early stages; the company intends to pursue more government contracts as confidence in execution grows. No specific commentary on a larger or longer-term order book or pending orders beyond these government contracts was provided during the call.

IN US

Sale is live|00:00:00left today

Thyrocare Technologies LtdQ3 FY23Healthcare Services

Thyrocare Technologies Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹546P/E: 43.9Market Cap: ₹7.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Franchise business revenue grew about 20% YoY with 8% volume growth; remaining growth driven by price mix (Rahul Guha, Page 17).
→Price hikes were marginal at 4-5%, major growth achieved through mix of larger Aarogyam packages, Jaanch test menu, vitamins, etc.
→Jaanch brand (diagnostic packages) reached ₹1 crore per month within 3 months and targets ₹25-30 crores revenue next year (Page 13).
→Hospital channel expansion is slow with only 2-3 hospitals currently, business still learning and not material yet (Page 14).
→Nuclear business expected to reach profitability with ₹12-12.5 crores quarterly revenue by H1 FY 2025 (Page 10).
→Overall 10% consolidated revenue growth YoY (Page 5) with franchise business strong and partnership business growing excluding API and B2G.
→Operating leverage likely to start kicking in FY 2025 with EBITDA margin of 28-30% maintained currently (Page 9).

Margin guidance

Category 3

→The company anticipates stable EBITDA margins in the 28-30% range for FY '24, with limited operating leverage due to ongoing investments in growth and business promotion.
→Operating leverage is expected to start kicking in from FY '25 onwards, potentially improving profitability.
→Nuclear business EBITDA margins are constrained by old equipment maintenance costs; normalized EBITDA expected around current levels, with growth in revenue to 12-12.5 crores quarterly expected by H1 FY '25.
→Franchise business grew 20% YoY, partnership business (excluding API & B2G) grew 22%, indicating strong revenue growth drivers.
→Price increases are marginal (~4-5%) with most revenue growth driven by a favorable product mix.
→International expansion (Tanzania) is underway, with plans to break even and expand in FY '25.
→Dividend payouts unlikely to increase in the near future as earnings are reinvested in growth and capital expenditure.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Currently, Thyrocare has about ₹30 crores of debt with a three-year tenure against assets, with no bank guarantee or collateral.
→In the immediate next 3 to 6 months, there is no plan for further debt funding as the company has enough cash.
→Future CAPEX investments will be evaluated to decide between equity, cash, or debt, depending on the best available options.
→The management views taking debt for healthcare equipment financing as prudent and cost-effective compared to using equity.
→They are open to taking more term loans if needed for business CAPEX, but no firm decision has been made yet.
→No anticipated increase in dividends reflected in future plans.

Order book

→The company has recently won government contracts for TB testing in Gujarat and Assam.
→These contracts total approximately ₹4.5 crores annually with a tenure of one year.
→Work on these contracts started from the current month of the call.
→The government business is still in early stages; the company intends to pursue more government contracts as confidence in execution grows.
→No specific commentary on a larger or longer-term order book or pending orders beyond these government contracts was provided during the call.

Capex plans

Yes

→H1 FY24 CAPEX spent: Rs. 46 crores.
→ - Rs. 16-17 crores on replacing 24 old machines.
→ - Rs. 16 crores on lab infrastructure improvements and expansions.
→ - Rs. 6 crores on LLP investments.
→ - Remaining on IT and other CAPEX.
→H2 FY24 planned CAPEX:
→ - Rs. 5 crores to replace older machines.
→ - Rs. 5 crores on physical infrastructure and IT overhaul.
→ - Rs. 10 crores on international expansion, primarily Tanzania lab setup.
→ - Total anticipated Rs. 20 crores in H2 FY24.
→FY25 estimated CAPEX: Around Rs. 50 crores (mainly maintenance CAPEX and expansions).
→Capital advances of Rs. 16 crores given for other business plans.
→Philosophy: Prefer debt financing (currently Rs. 30 crores term loan) over equity for equipment funding to optimize capital allocation.
→Expansion focus includes Tanzania (JV incorporated) and potential future geographies in East Africa, Middle East.

How does Thyrocare Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

1Thyrocare Technologies Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Thyrocare Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio